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Background:
 
 Recent registries have shown that recommended drugs for
the treatment of congestive heart failure (CHF) remain under-prescribed in
daily practice.
 
Aims:
 
 To compare prescription rates of CHF drugs in three French surveys
Impact Reco I, II and III.
 
Methods:
 
 We included outpatients followed by private cardiologists: 1947
in Impact Reco I (2005), 1974 in Impact Reco II (2005/2006) and 1574 in
Impact Reco III (2007), with NYHA class II-IV heart failure and a left ven-
tricular ejection fraction < 40%, and we compared treatment modalities. Rec-
ommended treatments and target doses were defined according to ESC
guidelines.
 
Results: 
 
There was an improvement in both the rate of prescription, and in
the proportion of patients reaching target dose or 50% of target dose of ACE
I, ARBs and beta blockers (see table
 
)
 
.
 
Conclusion: 
 
We observed an improvement with time in the management
of CHF outpatients with an increase in prescription rates of recommended
CHF drugs, as well as in the dosage used for ACE-I, ARB and beta-blockers,
although there is still room for improvement particularly for beta blockers.
These encouraging findings suggest a better awareness and implementation of
ESC guidelines by French private cardiologists. 
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Background:
 
 Hospitalizations for heart failure (HF) are associated
with high mortality and influence post-discharge survival in patients with both
reduced and preserved (
 
≥
 
50%) ejection fraction (EF). Several factors may pre-
cipitate HF hospitalizations. Heart failure with preserved ejection fraction
(HFPEF) is associated with considerable mortality. The characteristics and
prognostic impact of precipitating factors have not been studied in patients
with HFPEF.
 
Aims:
 
 To study the characteristics and impact on long-term outcome of HF
precipitating factors in patients surviving a first hospitalization for HFPEF.
 
Methods:
 
 We conducted a prospective observational study (11 healthcare
establishments, Somme, France) and included consecutive patients discharged
alive after a first hospitalization for HFPEF. Precipitating factors were col-
lected on admission (acute coronary syndromes [ACS], uncontrolled hyperten-
sion, arrhythmia, worsening of renal function [WRF], non-adherence to
therapy, and pneumonia). Mortality analyses used Cox models. Patients were
followed for 5 years.
 
Results:
 
 The cohort comprised 358 patients (76±10 years, 53% women).
Mean EF was 63±8%. One ore more precipitating factors were identified in
274 patients (76%). The most common were arrhythmia (37%), pneumonia
(16%), ACS (12%), and WRF (12%). Uncontrolled hypertension and non-
adherence to therapy were identified in 9% and 10% of cases, respectively.
Arrhythmia (HR1.35[1.02-1.80];p=0.03) and pneumonia (HR1.44[1.01-
2.07];p=0.05) were independently related to increased 5-year mortality. Com-
pared to patients without precipitating factors (n=84), those with one factor
(n=190; HR 1.67[1.15-2.43];p=0.007) as well as those with 
 
≥
 
2 factors (n=84;
HR 1.59[1.03-2.45];p=0.04) displayed excess 5-year mortality.
 
Conclusion:
 
 Factors that precipitate hospitalizations are frequent among
patients with HFPEF and predict increased long-term mortality. A more atten-
tive management of these factors may translate into survival benefits. 
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Background:
 
 Pulmonary hypertension (PH) is common in patients with
heart failure (HF) but, its relationship to symptoms and prognosis in a broad
representative population of patients with HF has rarely been investigated.
 
Methods:
 
 We interrogated a large database of consecutive referral to a HF
clinic serving a population of 600,000 people. Systolic HF (S-HF) was defined
as a LVEF
 
≤
 
45% and Preserved systolic LV HF (PS-HF) was defined as LVEF
>45% with an NT-proBNP value >400pg/mL. Right Ventricle Systolic Pres-
sure (RVSP) was assessed by the measurement of the tricuspid regurgitation
(TR) peak systolic velocity.
 
Results:
 
 Of 2135 patients referred, 1026 had S-HF, 354 had PS-HF and 533
had an accurate TR velocity measurement. Median (IQR) calculated RVSP for
HF patients was 25 (18-35mmHg). Amongst these patients, 270 had S-HF
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Prescription   
IMPACT 
I
2005
IMPACT 
II
2005/2006
IMPACT 
III
2007
Global population  1917 1974 1574
ACE I Number patients 
with prescription
N (%) 1361 (71.0) 1349 (68.3) 1099 (70.2)
Target dose % 48.7 57.3* 52.3•
50% Target dose % 80.4 84.5* 88.4†•
ARBs Number patients 
with prescription
N (%) 395 (20.6) 592 
(30.0)*
516 
(33.3)†•
Target dose % 9.1 7.4 20.7†•
50% Target dose % 52.9 49.7  68.6†•
Beta-
blockers
Number patients 
with prescription
N (%) 1245 (65.2) 1382 
(70.0)*
1229 
(78.3)†•
Target dose % 18.4 23.4*  25.7†
50% Target dose % 47.3 53.5*  59.9†•
* : p<0.05 Impact II vs I 
•: p<0.05 Impact III vs II 
† : p<0.05 Impact III vs I 
